ASCO 2023 | CheckMate 744: response-adapted therapy without autoSCT in pediatric low-risk R/R cHL
Paul Harker-Murray, MD, PhD, Medical College of Wisconsin, Milwaukee, WI, discusses the outcomes of a Phase II study, CheckMate 744 (NCT02927769), which evaluated a risk-stratified, response-adapted salvage treatment for pediatric and young adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). The study aimed to achieve high event-free survival (EFS) rates while minimizing late toxicity by avoiding high-dose chemotherapy and autologous stem cell transplantation (autoSCT). The results showed that patients in the low-risk cohort could achieve high complete molecular response rates without high-dose chemotherapy and autoSCT. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
